{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["15(23)"],"submitter":["Kang DH"],"pubmed_abstract":["To compare total en bloc spondylectomy (TES) with stereotactic ablative radiotherapy (SABR) for single spinal metastasis, we undertook a single center retrospective study. We identified patients who had undergone TES or SABR for a single spinal metastasis between 2000 and 2019. Medical records and images were reviewed for patient and tumor characteristics, and oncologic outcomes. Patients who received TES were matched to those who received SABR to compare local control and survival. A total of 89 patients were identified, of whom 20 and 69 received TES and SABR, respectively. A total of 38 matched patients were analyzed (19 TES and 19 SABR). The median follow-up period was 54.4 (TES) and 26.1 months (SABR) for matched patients. Two-year progression-free survival (PFS) and overall survival "],"journal":["Cancers"],"pagination":["5518"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10705804"],"repository":["biostudies-literature"],"pubmed_title":["Efficacy of Total En Bloc Spondylectomy versus Stereotactic Ablative Radiotherapy for Single Spinal Metastasis."],"pmcid":["PMC10705804"],"pubmed_authors":["Son HJ","Kang DH","Kim H","Chang BS","Kim JH","Chang SY","Lee W","Hong SH"],"additional_accession":[]},"is_claimable":false,"name":"Efficacy of Total En Bloc Spondylectomy versus Stereotactic Ablative Radiotherapy for Single Spinal Metastasis.","description":"To compare total en bloc spondylectomy (TES) with stereotactic ablative radiotherapy (SABR) for single spinal metastasis, we undertook a single center retrospective study. We identified patients who had undergone TES or SABR for a single spinal metastasis between 2000 and 2019. Medical records and images were reviewed for patient and tumor characteristics, and oncologic outcomes. Patients who received TES were matched to those who received SABR to compare local control and survival. A total of 89 patients were identified, of whom 20 and 69 received TES and SABR, respectively. A total of 38 matched patients were analyzed (19 TES and 19 SABR). The median follow-up period was 54.4 (TES) and 26.1 months (SABR) for matched patients. Two-year progression-free survival (PFS) and overall survival ","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Nov","modification":"2025-04-21T15:31:35.306Z","creation":"2025-02-19T00:45:59.825Z"},"accession":"S-EPMC10705804","cross_references":{"pubmed":["38067223"],"doi":["10.3390/cancers15235518"]}}